Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (17 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Laboratory service revenue
0
0
0
0
0
2
39
License fees
5
5
4
4
4
0
0
Total revenue
5
5
4
0
0
0
0
Total revenue
0
0
0
4
4
2
39
Cost of sales
0
0
0
0
0
4
25
Gross margin
5
5
4
4
4
-3
15
Research and development
4
9
22
42
28
29
34
General and administrative
10
6
8
10
14
30
58
Sales and Marketing
0
2
3
5
10
39
82
Total operating expenses
14
17
33
57
51
98
174
Restructuring charges
0
0
0
0
0
0
0
Loss from operations
-9
-12
-29
-53
-47
-101
-159
Investment income
0
0
0
0
0
1
1
Interest expense
0
0
0
0
0
0
0
Net loss
-9
-12
-29
-52
-47
-100
-158
Total other income
0
0
0
0
0
0
1
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 27, 2015 n/a
calculated values,
restated on Feb 24, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (37 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
n/a
79
36
13
13
58
41
Marketable securities
n/a
17
58
95
120
225
266
Accounts receivable, net
n/a
0
0
0
0
1
5
Inventory, Net
n/a
0
0
0
0
4
7
Prepaid expenses and other current assets
n/a
0
1
1
2
4
7
Total current assets
n/a
96
94
109
135
292
326
Computer equipment and computer software
n/a
0
1
1
1
8
14
Laboratory equipment
n/a
1
2
4
5
10
13
Leasehold improvements
n/a
0
0
0
5
6
7
Buildings
n/a
0
0
0
0
0
5
Assets under construction
n/a
0
0
0
3
2
8
Furniture and fixtures
n/a
0
0
0
0
1
1
Property and equipment, gross
n/a
1
3
5
14
26
48
Less-Accumulated depreciation
n/a
0
-1
-2
-3
-6
-14
Net property and equipment
n/a
1
3
3
11
20
34
Other long-term assets
n/a
0
0
0
0
1
4
Total assets
n/a
97
97
112
147
313
364
Liabilities and owners' equity
Accounts payable
n/a
1 1028000
1 765000
4 3652000
1 873000
3 2647000
3 3308000
Accrued liabilities
n/a
2 1987000
3 3069000
3 3327000
6 5694000
14 13960000
22 22253000
Deferred license fees, current portion
n/a
4 4143000
4 4143000
4 4143000
0 294000
0 0
0 0
Debt and capital lease obligation, current portion
n/a
0 0
0 0
0 333000
0 351000
0 360000
0 166000
Other short-term liabilities
n/a
0 0
0 0
0 0
1 540000
1 554000
1 996000
Total current liabilities
n/a
7 7158000
8 7977000
11 11455000
8 7752000
18 17521000
27 26723000
Long-term debt
n/a
1 1000000
1 1000000
1 1000000
1 1000000
1 1000000
5 4789000
Long-term accrued interest
n/a
0 21000
0 42000
0 63000
0 84000
0 106000
0 0
Other long-term liabilities
n/a
0 0
0 0
1 711000
0 360000
4 3599000
5 4601000
Lease incentive obligation, less current portion
n/a
0 0
0 0
0 0
2 2115000
2 1614000
1 1061000
Deferred license fees, less current portion
n/a
9 8582000
4 4439000
0 295000
0 0
0 0
0 0
Total liabilities
n/a
0 0
0 0
0 0
11 11311000
24 23840000
37 37174000
Commitments and contingencies
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at March 31, 2016 and December 31, 2015
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Common stock, $0.01 par value Authorized—200,000,000 shares issued and outstanding—97,737,710 and 96,674,786 shares at March 31, 2016 and December 31, 2015
n/a
1 522000
1 566000
1 639000
1 711000
1 887000
1 968000
Additional paid-in capital
n/a
272 272380000
305 304767000
372 372123000
455 455239000
709 709019000
905 904931000
Accumulated other comprehensive loss
n/a
0 1000
0 -14000
0 78000
0 125000
0 -115000
0 -433000
Accumulated deficit
n/a
-193 -193149000
-222 -221824000
-274 -274245000
-321 -320759000
-421 -420807000
-579 -578610000
Total stockholders' equity
n/a
80 79754000
83 83495000
99 98595000
135 135316000
289 288984000
327 326856000
Total liabilities and stockholders’ equity
n/a
97 96515000
97 96953000
112 112119000
147 146627000
313 312824000
364 364030000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Feb 27, 2015 n/a restated on Feb 24, 2016 n/a restated on May 3, 2016 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (39 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net loss
-9
-12
-29
-52
-47
-100
-158
Depreciation and amortization of fixed assets
0
0
0
1
1
4
8
Loss on disposal of property and equipment
0
0
0
0
0
0
0
Stock-based compensation
3
2
4
5
8
12
18
Warrant licensing expense
2
0
0
0
0
0
0
Restricted stock licensing expense
0
0
0
1
0
0
0
Amortization of other liabilities
0
0
0
0
0
0
-1
Amortization of deferred license fees
-5
-5
-4
-4
-4
0
0
Forgiveness of long-term debt
0
0
0
0
0
0
-1
Amortization of premium on short-term investments
0
0
0
1
1
1
1
Amortization of intangible assets
0
0
0
0
0
0
0
Accounts receivable, net
0
0
0
0
0
-1
-4
Inventory, Net
0
0
0
0
0
-4
-3
Prepaid expenses and other current assets
0
0
-1
0
-2
-1
-3
Accounts payable
-1
1
0
3
-3
2
1
Accrued liabilities
0
1
2
1
2
8
7
Lease incentive obligation
-2
-1
0
0
3
0
-1
Accrued interest
0
0
0
0
0
0
0
Net cash used in operating activities
-13
-13
-27
-45
-40
-81
-134
Purchases of marketable securities
-19
-24
-87
-96
-99
-209
-205
Maturities of marketable securities
16
10
46
58
72
104
162
Purchases of property and equipment
0
-1
-2
-1
-9
-12
-20
Purchases of intangible assets
0
0
0
0
0
0
-2
Net cash used in investing activities
-3
-15
-43
-38
-35
-117
-65
Proceeds from Collaborators
17
2
0
0
0
0
0
Proceeds from exercise of common stock options
1
0
1
2
1
3
1
Proceeds from sale of common stock, net of issuance costs
8
82
27
58
73
239
174
Payments on capital lease obligations
0
0
0
0
0
0
0
Payments on mortgage payable
0
0
0
0
0
0
0
Proceeds from mortgage payable
0
0
0
0
0
0
5
Proceeds from New Market Tax Credit financing agreements
1
0
0
0
0
2
0
Proceeds in connection with the Company's employee stock purchase plan
0
0
0
0
0
1
2
Net cash provided by financing activities
32
85
28
60
75
244
182
Proceeds from Issuance of Private Placement
6
0
0
0
0
0
0
Decrease in restricted cash
0
1
0
0
0
0
0
Payment for repurchase of stock options
0
0
0
0
0
0
0
Effects of exchange rate on cash and cash equivalents
0
0
0
0
0
0
0
Net increase (decrease) in cash and cash equivalents
17
57
-43
-22
0
45
-17
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 28, 2014 n/a
calculated values,
restated on Feb 27, 2015 n/a
calculated values,
restated on Feb 24, 2016 n/a
calculated values,
restated on Feb 24, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Sumo